Development Center for Biotechnology

 


DCB CEO Wu

     CEO: Dr. Chung-hsiun WuDCB logo 
     Founded Date: 1984
     Tel: +886-2-2695-6933 
     Address: No. 101, Lane 169, Kang-ning Street, Xizhi Dist., New Taipei City
     Website: http://www.dcb.org.tw/


 

Company Profile:

The Development Center for Biotechnology (DCB) of Taiwan is a not-for-profit organization founded in 1984, based on government grants and private donations. DCB's mission is to accelerate the development of Taiwan's biotech industry, by way of building infrastructures, developing key technologies, promoting cooperation and industrialization, and training talented workforces, in coordination with governmental, industrial, and academic institutions.

DCB plays the pivotal role of “2nd-baton runner” in the “relay race” of biotech-drug development of Taiwan. After receiving discovery research outputs from the “1st-baton runner”– the academia, and adding value by performing necessary preclinical development work, DCB hands over the results to the “3rd-baton runner”- the industry, for clinical development, manufacturing and marketing. Positioned as a "Preclinical Value-Adding R&D and Integrated Service Center for Biopharmaceuticals", DCB provides all-rounded services, ranging from R&D to business development, to the biotech drug industry through resource integration and value creation.

DCB's headquarters and R&D Division are based in the Da-Hu Science Park of New Taipei City, with its Industrial Promotion Division located in the nearby Nangang Biotech Square. There are currently about 400 employees at DCB; over 80% of them have Ph.D. or M.S. degrees. The R&D Division comprised Institute of Biologics, Institute of Pharmaceutics, Institute for Drug Evaluation Platform, and Exploratory Research Laboratory. In addition to managing the NanKang Biotech Incubation Center and the Biotechnology & Pharmaceutical Industries Promotion Office, the Industrial Promotion Division provides various business services, including technology transfer and product commercialization, to facilitate the upgrading and transformation of Taiwan’s biotech industry.

Pipeline:

研發產品線生技中心